Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 89

Related Citations for PubMed (Select 19773083)

1.

Imatinib achieved complete cytogenetic response in a CML patient received 32-year indirubin and its derivative treatment.

Chen F, Li L, Ma D, Yan S, Sun J, Zhang M, Ji C, Hou M.

Leuk Res. 2010 Feb;34(2):e75-7. doi: 10.1016/j.leukres.2009.09.001. Epub 2009 Sep 20. No abstract available.

PMID:
19773083
2.

Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib.

Lin F, Drummond M, O'Brien S, Cervantes F, Goldman J, Kaeda J.

Blood. 2003 Aug 1;102(3):1143. No abstract available.

3.

Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.

Pienkowska-Grela B, Woroniecka R, Solarska I, Kos K, Pastwińska A, Konopka L, Majewski M.

Cancer Genet Cytogenet. 2007 Apr 15;174(2):111-5.

PMID:
17452251
4.

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.

Kantarjian HM, Cortes JE, O'Brien S, Giles F, Garcia-Manero G, Faderl S, Thomas D, Jeha S, Rios MB, Letvak L, Bochinski K, Arlinghaus R, Talpaz M.

Blood. 2003 Jan 1;101(1):97-100. Epub 2002 Aug 29.

5.

CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib.

Moravcová J, Rulcová J, Polák J, Zemanová Z, Klamová H, Haskovec C.

Leuk Res. 2005 Nov;29(11):1365-6. No abstract available.

PMID:
15876454
6.

Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.

Braziel RM, Launder TM, Druker BJ, Olson SB, Magenis RE, Mauro MJ, Sawyers CL, Paquette RL, O'Dwyer ME.

Blood. 2002 Jul 15;100(2):435-41.

7.

Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.

Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M, Poerio A, Soverini S, Bassi S, Cilloni D, Bassan R, Breccia M, Lauria F, Izzo B, Merante S, Frassoni F, Paolini S, Montefusco E, Baccarani M, Martinelli G; GIMEMA Working Party on Chronic Myeloid Leukemia.

Clin Cancer Res. 2006 May 15;12(10):3037-42.

8.

[Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].

Zhang GC, Zheng D, Li QH, Li XH, Cai CC, Luo SK, Li J, Peng AH, Tong XZ, Tan EX, Hong WD.

Ai Zheng. 2004 Dec;23(12):1696-9. Chinese.

PMID:
15601563
9.

Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib.

Avery S, Nadal E, Marin D, Olavarria E, Kaeda J, Vulliamy T, Brito Babapulle F, Goldman JM, Apperley JF.

Leuk Res. 2004 May;28 Suppl 1:S75-7.

PMID:
15036946
10.

Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.

Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A.

Cancer. 2005 Apr 15;103(8):1659-69.

11.

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.

Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M.

Blood. 2002 May 15;99(10):3547-53.

12.

Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.

Kim YJ, Kim DW, Lee S, Min CK, Goh HG, Kim SH, Lee JY, Kim YL, Kim HJ, Kim HJ, Lee JW, Kim TG, Min WS, Kim CC.

Biol Blood Marrow Transplant. 2004 Oct;10(10):718-25.

PMID:
15389438
13.

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.

Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL, Bhatia R.

Blood. 2005 Mar 1;105(5):2093-8. Epub 2004 Sep 2.

14.

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.

Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H.

Clin Cancer Res. 2005 May 1;11(9):3425-32.

15.

Imatinib in Philadelphia chromosome-positive chronic phase CML patients: molecular and cytogenetic response rates and prediction of clinical outcome.

Le Coutre P, Kreuzer KA, Na IK, Schwarz M, Lupberger J, Holdhoff M, Baskaynak G, Gschaidmeier H, Platzbecker U, Ehninger G, Prejzner W, Huhn D, Schmidt CA.

Am J Hematol. 2003 Aug;73(4):249-55.

PMID:
12879428
16.
17.

Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.

Lange T, Bumm T, Otto S, Al-Ali HK, Kovacs I, Krug D, Köhler T, Krahl R, Niederwieser D, Deininger MW.

Haematologica. 2004 Jan;89(1):49-57.

18.

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.

Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Shan J, Letvak L, Thomas D, Faderl S, Ferrajoli A, Cortes J.

Blood. 2004 Apr 15;103(8):2873-8. Epub 2003 Dec 24.

19.

Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.

Hardling M, Wei Y, Palmqvist L, Swolin B, Stockelberg D, Gustavsson B, Ekeland-Sjöberg K, Wadenvik H, Ricksten A.

Med Oncol. 2004;21(4):349-58.

PMID:
15579919
20.

Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease.

Franceschino A, Tornaghi L, Piazza R, Pogliani E, Gambacorti Passerini C.

Haematologica. 2006 Jun;91(6 Suppl):ECR14. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk